Daicel Corporation
4202.T · Tokyo Stock Exchange · JPY
1.620,00JPY
+25,00 (+1,57 %)Stand 10. Nov., 2:30
Kennzahlen
- Eröffnung
- 1.613,00
- Vortag
- 1.595,00
- Tagesspanne
- 1.602,50 – 1.632,00
- 52 Wochen
- 1.112,50 – 1.658,00
- Volumen
- 572.500
- Ø Volumen
- 1,21 Mio.
- Börsenwert
- 369,66 Mrd. ¥
- KGV
- 41,4
- Gewinn je Aktie (TTM)
- 39,11
- Dividendenrendite
- 4,0 %
- Beta
- 0,5
- Nächste Zahlen
- 3. Feb. 2027
Finanzen
| JPY | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Umsatz | 579,63 Mrd. | 586,53 Mrd. | 558,06 Mrd. | 538,03 Mrd. | 467,94 Mrd. |
| Herstellungskosten | 433,34 Mrd. | 420,69 Mrd. | 397,67 Mrd. | 390,98 Mrd. | 328,26 Mrd. |
| Bruttogewinn | 146,29 Mrd. | 165,84 Mrd. | 160,39 Mrd. | 147,04 Mrd. | 139,68 Mrd. |
| Forschung und Entwicklung | 0 | 25,93 Mrd. | 23,39 Mrd. | 21,88 Mrd. | 20,74 Mrd. |
| Vertrieb und Verwaltung | 104,22 Mrd. | 78,9 Mrd. | 74,6 Mrd. | 77,66 Mrd. | 68,24 Mrd. |
| Operatives Ergebnis | 42,07 Mrd. | 61,01 Mrd. | 62,39 Mrd. | 47,51 Mrd. | 50,7 Mrd. |
| EBITDA | 72,71 Mrd. | 108,86 Mrd. | 111,4 Mrd. | 87,98 Mrd. | 75,84 Mrd. |
| Nettogewinn | 10,18 Mrd. | 49,48 Mrd. | 55,84 Mrd. | 40,68 Mrd. | 31,25 Mrd. |
| Gewinn je Aktie (verwässert) | 38,74 | 181,44 | 197,56 | 138,87 | 104,14 |
Bewertung
Letzte 12 Monate
- KGV
- 41,4
- Kurs-Umsatz-Verhältnis
- 0,6
- Kurs-Buchwert-Verhältnis
- 1,1
- PEG
- -0,6
- Bruttomarge
- 25,0 %
- Operative Marge
- 7,3 %
- Nettomarge
- 1,7 %
- Verschuldungsgrad
- 0,8
- EV/EBITDA
- 8,3
- Eigenkapitalrendite
- 2,7 %
- Kapitalrendite (ROIC)
- 2,4 %
- Free-Cashflow-Rendite
- 0,0 %
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Bruttomarge | 25,2 % | 28,3 % | 28,7 % | 27,3 % | 29,9 % |
| Operative Marge | 7,3 % | 10,4 % | 11,2 % | 8,8 % | 10,8 % |
| Nettomarge | 1,8 % | 8,4 % | 10,0 % | 7,6 % | 6,7 % |
| KGV | 31,6 | 7,2 | 7,2 | 7,2 | 7,8 |
| Kurs-Umsatz-Verhältnis | 0,6 | 0,6 | 0,7 | 0,5 | 0,5 |
| Kurs-Buchwert-Verhältnis | 0,9 | 1,0 | 1,1 | 1,0 | 0,9 |
| Verschuldungsgrad | 0,9 | 0,8 | 0,8 | 1,1 | 1,0 |
| Liquidität 3. Grades | 2,0 | 1,9 | 2,0 | 1,8 | 2,3 |
| Dividendenrendite | 4,9 % | 4,3 % | 3,2 % | 3,6 % | 3,9 % |
| Unternehmenswert | 557,44 Mrd. | 574,81 Mrd. | 635,36 Mrd. | 521,09 Mrd. | 440,61 Mrd. |
| EV/EBITDA | 7,7 | 5,3 | 5,7 | 5,9 | 5,8 |
| Eigenkapitalrendite | 2,9 % | 13,7 % | 15,6 % | 13,8 % | 11,5 % |
| Kapitalrendite (ROIC) | 2,6 % | 6,9 % | 6,5 % | 5,5 % | 5,9 % |
| Free-Cashflow-Rendite | 0,8 % | 6,6 % | 2,7 % | −7,0 % | −0,2 % |
Wachstum
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Umsatz | −1,2 % | +5,1 % | +3,7 % | +15,0 % | +18,9 % |
| Bruttogewinn | −11,8 % | +3,4 % | +9,1 % | +5,3 % | +23,1 % |
| Operatives Ergebnis | −31,0 % | −2,2 % | +31,3 % | −6,3 % | +54,5 % |
| Nettogewinn | −79,4 % | −11,4 % | +37,2 % | +30,2 % | +58,5 % |
| Gewinn je Aktie | −78,6 % | −8,2 % | +42,3 % | +33,3 % | +59,8 % |
| Freier Cashflow | −89,3 % | +111,0 % | +154,1 % | −3.999,6 % | −102,2 % |
| Dividende je Aktie | +8,9 % | +22,3 % | +25,1 % | +13,1 % | −6,7 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2027 | FY 2028 | FY 2029 | |
|---|---|---|---|
| Umsatz (Ø) | 621,27 Mrd. | 634,83 Mrd. | 666,86 Mrd. |
| Umsatz (Tief – Hoch) | 601,72 Mrd. – 652,87 Mrd. | 607,15 Mrd. – 671,73 Mrd. | 633,73 Mrd. – 702,7 Mrd. |
| Gewinn je Aktie (Ø) | 137,88 | 148,24 | 178,65 |
| Gewinn je Aktie (Tief – Hoch) | 106,59 – 161,23 | 110,59 – 180,96 | 144,18 – 210,21 |
| Analysten | 8 | 8 | 7 |
Quartalszahlen
Nächste Zahlen: 3. Feb. 2027| Nov. 2026 | Juli 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 30,79 | 21,46 | 51,88 | 50,21 | 58,90 | 34,92 | 42,57 | 57,00 |
| Gewinn je Aktie · Tatsächlich | 35,77 | 36,65 | -96,24 | 64,09 | 34,61 | 36,29 | 21,14 | 44,12 |
| Abweichung | +16,17 % | +70,78 % | −285,51 % | +27,64 % | −41,24 % | +3,92 % | −50,34 % | −22,60 % |
| Umsatz · Tatsächlich | 160,46 Mrd. | 152,38 Mrd. | 154,81 Mrd. | 147,71 Mrd. | 137,85 Mrd. | 139,27 Mrd. | 153,99 Mrd. | 142,86 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 30. März 2027 | 30. März 2027 | 40,00 |
| 29. Sept. 2026 | 2. Dez. 2026 | 35,00 |
| 30. März 2026 | 22. Juni 2026 | 30,00 |
| 29. Sept. 2025 | 2. Dez. 2025 | 30,00 |
| 28. März 2025 | 23. Juni 2025 | 30,00 |
| 27. Sept. 2024 | 3. Dez. 2024 | 30,00 |
| 28. März 2024 | 24. Juni 2024 | 25,00 |
| 28. Sept. 2023 | 4. Dez. 2023 | 25,00 |
| 30. März 2023 | 26. Juni 2023 | 20,00 |
| 29. Sept. 2022 | 2. Dez. 2022 | 18,00 |
| 30. März 2022 | 23. Juni 2022 | 16,00 |
| 29. Sept. 2021 | 2. Dez. 2021 | 16,00 |
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
Über das Unternehmen
Daicel Corporation, a Japanese enterprise founded in Osaka in 1919, conducts its business operations across Japan, Asia, North America, and Europe. The company is a key producer and distributor of a broad array of products, including cellulosic derivatives, organic chemicals, diverse plastics, and pyrotechnic devices. Its extensive activities are organized into distinct segments: Medical/Healthcare, Smart, Safety, Materials, Engineering Plastics, and other specialized areas. In the Medical/Healthcare sector, Daicel supplies various cosmetic components such as 1,3-Butylene glycol, polyglycerin, and thickeners, in addition to natural health food ingredients and dietary supplements. For the pharmaceutical industry, it provides specialized chiral and achiral columns, a variety of chiral and bio reagents, and DNA/RNA-based probes, supported by comprehensive analytical, purification, synthesis, formulation, and specialized analytical tool services. The "Smart" segment focuses on advanced materials for the electronics industry, offering triacetylcellulose and films for display technologies, solvents for electronic applications, polymers for resist processes, and cleaning agents for semiconductors. Moreover, Daicel contributes to visualization technologies with its optical components, lens units, silver nanoparticle inks, and organic semiconductor devices. Within the Safety domain, the company manufactures inflators for vehicle airbags and pyro-fuses, alongside safety mechanisms for non-automotive products. Daicel is also a significant supplier of foundational chemicals and raw materials, including acetic acid and its derivatives, cellulose acetate, and acetate tow for resins, inks, and paint solvents. It further develops specialty chemicals such as cycloaliphatic epoxies, caprolactone, ketene derivatives, and alkylamines, which are vital for electrical materials and coatings. For the Engineering Plastics segment, Daicel delivers a wide selection of plastic solutions, encompassing engineering plastics, plastic compound products, functional sheets, molded trays, and packaging films. Beyond these core offerings, the company also produces water treatment systems and diffusers tailored for diverse industrial requirements. Daicel's comprehensive portfolio plays a crucial role in various sectors, including transportation, electronics, medical care, personal care, daily life, and environmental and energy applications. The company, which was initially named Daicel Chemical Industries, Ltd., officially adopted its current name, Daicel Corporation, in October 2011.
Führung
- Yoshimi OgawaExecutive Board Chairman
- Yasuhiro SakakiPresident, Chief Executive Officer & Director
- Kotaro SugimotoSenior Managing Executive Officer, Head of Corporation Support HQ & Representative Director
- Naotaka KawaguchiSenior Managing Executive Officer, Senior Managing Executive Officer & Director & Director
- Seiji YamakadoExecutive Officer & Head of Customer Center
- Takashi MiyamotoSenior Managing Executive Officer
- CEO
- Yasuhiro Sakaki
- Mitarbeitende
- 11.034
- Hauptsitz
- Osaka, OS, JP
- Sektor
- Basic Materials
- Branche
- Chemicals - Specialty
- Börsengang
- 1. Jan. 2001
- Website
- daicel.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.